BridgeBio Pharma Inc. will report fourth-quarter and full-year 2025 results after the market closes on Tuesday, February 24, a closely watched print for a rare-disease developer seeking to prove its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results